Septerna to Present at TD Cowen 46th Annual Health Care Conference

Septerna (Nasdaq: SEPN) announced that CEO and co-founder Jeffrey Finer, M.D., Ph.D. will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 3:10 p.m. ET in Boston.

Rhea-AI Summary

Septerna (Nasdaq: SEPN) announced that CEO and co-founder Jeffrey Finer, M.D., Ph.D. will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 3:10 p.m. ET in Boston.

A live webcast will be available on the company investor website and will be archived for at least 30 days for on-demand viewing.

Argus Feb 24 session

+10.21% close to close Open Argus

Details

News Market Reaction – SEPN

On Feb 24, the day this news came out, SEPN closed 10.21% above the previous close.

Data tracked by StockTitan Argus for the Feb 24 session.

Key Figures

Conference edition: 46th Presentation date: March 3, 2026 Presentation time: 3:10 p.m. ET +1 more

Conference edition

46th

TD Cowen Annual Health Care Conference

Presentation date

March 3, 2026

Scheduled conference presentation in Boston

Presentation time

3:10 p.m. ET

Scheduled time of company presentation

Webcast archive period

30 days

Duration webcast will remain available after presentation

Historical Context

5 past events · Latest: Feb 10

5 events

1. Feb 10

   Inducement option grant

   24h Move

   -1.4%

   Inducement stock option grant to new Chief Legal Officer under Nasdaq rule.

2. Feb 10

   Clinical data presentation

   24h Move

   +0.4%

   Announcement of Phase 1 SEP-631 data presentation at 2026 AAAAI meeting.

3. Jan 08

   Leadership appointment

   24h Move

   -1.7%

   Appointment of industry veteran Mark A. Wilson as Chief Legal Officer.

4. Dec 17

   JP Morgan conference

   24h Move

   +1.2%

   Planned CEO presentation at 44th Annual J.P. Morgan Healthcare Conference.

5. Nov 25

   Evercore conference

   24h Move

   -1.9%

   Participation in fireside chat at 8th Annual Evercore Healthcare Conference.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

g protein-coupled receptor, gpcr

2 terms

g protein-coupled receptor medical

"pioneering a new era of G protein-coupled receptor (GPCR) drug discovery"

A G protein-coupled receptor is a protein on a cell’s surface that acts like an antenna: it detects signals such as hormones, neurotransmitters or drugs outside the cell and passes that message inside to change cell behavior. Investors care because roughly a third of marketed medicines act on these receptors, so a company’s success in targeting or modulating a specific receptor can determine the value of drug candidates, regulatory risk, and future revenue potential.

gpcr medical

"pioneering a new era of G protein-coupled receptor (GPCR) drug discovery"

G protein-coupled receptors (GPCRs) are a large family of proteins on cell surfaces that act like locks sensing chemical signals — when the right key binds, they trigger internal cell responses. They matter to investors because GPCRs are the target of many marketed drugs and experimental therapies; success or failure in developing a GPCR-targeting drug can change a company’s revenue prospects, clinical progress, and licensing value, much like winning control of a widely used distribution channel.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, announced that Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna, will present at the TD Cowen 46^th Annual Health Care Conference on Tuesday, March 3, 2026, at 3:10 p.m. ET in Boston.

A live webcast of the presentation will be available in the investors section of the company’s website at www.septerna.com. The webcast will be archived for at least 30 days following the presentation.

About Septerna
Septerna, Inc. is a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR therapies for patients with significant unmet needs. The company’s proprietary Native Complex Platform^® is designed to enable new approaches to GPCR drug discovery and has led to the development of a diverse pipeline of novel oral small molecule drug candidates. Septerna is advancing programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas, both independently and with partners. For more information, please visit www.septerna.com.

Investor Contact:
Renee Leck, THRUST
renee@thrustsc.com

Media Contact:
Carly Scaduto, THRUST
carly@thrustsc.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Septerna (SEPN) present at the TD Cowen 46th Annual Health Care Conference?

Septerna will present at TD Cowen on March 3, 2026, at 3:10 p.m. ET in Boston. According to the company, CEO Jeffrey Finer, M.D., Ph.D., will deliver the presentation and represent the company to investors and analysts.

How can investors watch the Septerna (SEPN) presentation on March 3, 2026?

Investors can watch a live webcast on Septerna’s investor website during the March 3, 2026 presentation. According to the company, the webcast link will be posted on the investor section of septerna.com for real-time viewing.

Who will present for Septerna (SEPN) at the TD Cowen conference?

Jeffrey Finer, M.D., Ph.D., CEO and co-founder, will present Septerna’s session at TD Cowen on March 3, 2026. According to the company, Dr. Finer will discuss company progress and strategic updates during the scheduled timeslot.

Will the Septerna (SEPN) webcast be archived after the March 3 presentation and for how long?

Yes; Septerna will archive the March 3, 2026 presentation webcast for at least 30 days following the live event. According to the company, the archived webcast will be accessible via the investor section of septerna.com for on-demand playback.

What topics will Septerna (SEPN) cover during the TD Cowen presentation on March 3, 2026?

Septerna is expected to discuss its GPCR drug discovery platform and ongoing clinical-stage programs during the March 3 presentation. According to the company, CEO Jeffrey Finer will present program progress, development milestones, and the company’s strategic outlook to investors.